UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety Surveillance of Traditional Chinese Medicine: Current and Future

Drug safety, 2015-02, Vol.38 (2), p.117-128

2015

Volltextzugriff (PDF)

YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment

Scientific reports, 2021-06, Vol.11 (1), p.13482-12, Article 13482

2021

Volltextzugriff (PDF)

PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment

Scientific reports, 2015-03, Vol.5 (1), p.9384, Article 9384

2015

Volltextzugriff (PDF)

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer

Cancer chemotherapy and pharmacology, 2014-02, Vol.73 (2), p.373-380

2014

Volltextzugriff (PDF)

Metabolomics mechanism of traditional soy sauce associated with fermentation time

Food science and human wellness, 2022-03, Vol.11 (2), p.297-304

2022

Volltextzugriff (PDF)

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy

Frontiers in pharmacology, 2023-10, Vol.14, p.1244655-1244655

2023

Volltextzugriff (PDF)

Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)

Frontiers in pharmacology, 2018-11, Vol.9, p.1324-1324

2018

Volltextzugriff (PDF)

Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS)

Journal of Chromatography A, 2010-09, Vol.1217 (37), p.5785-5793

2010

Volltextzugriff (PDF)

Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy

Rapid communications in mass spectrometry, 2007-11, Vol.21 (22), p.3593-3607

2007

Volltextzugriff (PDF)

Study of Malformin C, a Fungal Source Cyclic Pentapeptide, as an Anti-Cancer Drug

PloS one, 2015-11, Vol.10 (11), p.e0140069

2015

Volltextzugriff (PDF)

Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma

Anticancer research, 2009-10, Vol.29 (10), p.4083

2009

Volltextzugriff (PDF)

Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment

BMC medical genomics, 2011-05, Vol.4 (1), p.38-38, Article 38

2011

Volltextzugriff (PDF)

A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906

Chinese medicine, 2010-08, Vol.5 (1), p.30-30, Article 30

2010

Volltextzugriff (PDF)

Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates

Cancer research (Chicago, Ill.), 2002-03, Vol.62 (6), p.1624-1631

2002

Volltextzugriff (PDF)

Increased Anti-P-glycoprotein Activity of Baicalein by Alkylation on the A Ring

Journal of medicinal chemistry, 2004-10, Vol.47 (22), p.5555-5566

2004

Volltextzugriff (PDF)

The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity

Science translational medicine, 2010-08, Vol.2 (45), p.45ra59

2010

Volltextzugriff (PDF)

A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants

Cancer research (Chicago, Ill.), 2024-07, Vol.84 (13), p.2169-2180

2024

Volltextzugriff (PDF)

Abstract 3138: Mechanism based quality control (MBQC) for the four-herb Chinese medicine formulation, PHY906(YIV-906) and other herbal products

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3138-3138

2017

Volltextzugriff (PDF)

Abstract 5584: PHY906(YIV-906), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Immune checkpoint blockade therapy: anti-PDL1, anti-PD1, anti-PD1/CTLA4 against melanoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5584-5584

2017

Volltextzugriff (PDF)

Abstract 2724: YIV906 (PHY906) enhanced the antitumor activity of immune checkpoint blockade therapy: Anti-PD1 against liver cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2724-2724

2018

Volltextzugriff (PDF)

Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria

The Journal of biological chemistry, 1999-02, Vol.274 (8), p.4620-4625

1999

Volltextzugriff (PDF)

Abstract 526: Alternative format bispecific antibodies targeting multiple oncogenic FGFR3 mutations in bladder cancer through different mechanisms

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.526-526

2020

Volltextzugriff (PDF)

Abstract 2252: YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against liver cancer by changing the tumor micro-environment associated with M1 macrophages infiltration

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2252-2252

2019

Volltextzugriff (PDF)

Abstract B129: A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.B129-B129

2023

Volltextzugriff (PDF)

Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice

Cancer chemotherapy and pharmacology, 2018-06, Vol.81 (6), p.1025-1033

2018

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(46)
Buchkapitel
(1)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(22)
Humans
(15)
Animals
(9)
Female
(9)
Mice
(9)
Oncology
(8)
Pharmacology & Pharmacy
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(6)
Technology
(6)
Antineoplastic Agents
(5)
Camptothecin - Analogs & Derivatives
(5)
Dose-Response Relationship, Drug
(5)
Drugs, Chinese Herbal - Pharmacology
(5)
Medicine
(5)
Pharmacology. Drug Treatments
(5)
Physical Sciences
(5)
Tumors
(5)
Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Safety Surveillance of Traditional Chinese Medicine: Current and Future

YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment

PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer

Metabolomics mechanism of traditional soy sauce associated with fermentation time

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy

Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)

Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS)

Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy

Study of Malformin C, a Fungal Source Cyclic Pentapeptide, as an Anti-Cancer Drug

Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma

Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment

A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906

Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates

Increased Anti-P-glycoprotein Activity of Baicalein by Alkylation on the A Ring

The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity

A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants

Abstract 3138: Mechanism based quality control (MBQC) for the four-herb Chinese medicine formulation, PHY906(YIV-906) and other herbal products

Abstract 5584: PHY906(YIV-906), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Immune checkpoint blockade therapy: anti-PDL1, anti-PD1, anti-PD1/CTLA4 against melanoma

Abstract 2724: YIV906 (PHY906) enhanced the antitumor activity of immune checkpoint blockade therapy: Anti-PD1 against liver cancer

Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria

Abstract 526: Alternative format bispecific antibodies targeting multiple oncogenic FGFR3 mutations in bladder cancer through different mechanisms

Abstract 2252: YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against liver cancer by changing the tumor micro-environment associated with M1 macrophages infiltration

Abstract B129: A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models

Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice

Suchergebnisse filtern